1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
CLASSYS Inc.

CLASSYS Inc.

KKRX:214150
27,750.00
KRW
-650.00
(-2.29%)
2,050.33EPS
22.10P/E
3.04TMarket Cap
Nov 05Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
4,953.33
632.33
773.13
1,297.4
1,182.03
1,554.72
2,191.61
2,802.85
3,777.8
5,149.21
5,654.7
Basic EPS, GAAP
14
1,285.8
-93
242
534
590
677
1,165
1,155
1,522
2,017
2,108.46
Free Cash Flow per Basic Share
7.09
1,017.25
-420.54
18.63
515.48
574.19
51.46
413.52
910.61
1,430.9
2,211.86
1,689.94
Dividend per Share
- -
- -
- -
7.88
13.87
45.77
60
66.01
116.26
199.04
257.35
- -
Book Value per Share
1,911.87
2,968.7
580.29
823.63
1,365.92
1,912.51
2,530.17
3,564
4,429.73
6,930.62
8,478.63
8,425.79
Tangible Book Value per Share
1,911.87
2,962.78
578.68
821.16
1,354.88
1,899.81
2,512.8
3,541.05
4,385.63
4,778.79
6,337.64
5,932.27
Basic Weighted Avg Shares
5
6
55
61
63
65
65
65
64
64
65
65
Sales/Revenue/Turnover
- -
27,243
34,868
47,482
81,133
76,461
100,597
141,803
180,123
242,939
336,820
369,113
Operating Margin (%)
- -
30.34
30.98
36.81
51.41
53.11
51.41
48.57
49.76
50.4
50.65
46.04
Depreciation Expense
- -
115
222
761
1,400
2,083
2,523
3,900
4,278
7,218
14,641
15,449
Net Income, GAAP
64
7,072
-5,128
14,863
33,394
38,165
43,805
75,379
74,225
97,875
131,936
137,631
Effective Tax Rate (%)
15.35
19.39
- -
16.44
19.98
2.87
21.25
22.1
20.9
23.75
21.74
24.75
Profit Margin (%)
- -
25.96
-14.71
31.3
41.16
49.91
43.54
53.16
41.21
40.29
39.17
37.29
Working Capital
- -
12,881
13,270
11,771
32,160
69,563
56,347
111,563
156,491
105,298
215,568
118,822
LT Debt
1,340
- -
13,458
9,600
79
172
35,291
64,941
62,489
11,760
62,820
6,732
Total Equity
10,515
16,328
35,092
51,043
87,917
123,757
163,744
229,554
283,500
452,644
551,674
555,097
Return on Invested Capital (%)
- -
45.9
- -
23.37
38.58
33.76
24.39
20.57
20.98
20.32
21.82
20.32
Return on Capital (%)
- -
50.19
- -
24.87
40.92
34.54
27.11
31.15
23.44
22.35
22.63
22.67
Return on Common Equity (%)
- -
52.69
-19.95
34.51
48.06
36.06
30.47
38.33
28.93
26.54
26.21
26.32

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
23,972
139,524
141,637
LT Borrowings
62,775
1,159
5,581
LT Finance Leases
45
1,392
1,151
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
65
65
65
Market Capitalization
3,554,473
3,293,595
3,039,238

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
295,772
362,656
317,723
Cash, Cash Equivalents & STI
207,561
181,685
136,102
Accounts Receivable, Net
48,372
108,648
98,395
Inventories
30,096
59,120
64,897
Total Current Liabilities
80,204
252,336
198,901
Payables & Accruals
- -
- -
- -
ST Debt
23,972
139,524
141,637
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.62%
35.51%
21.88%
Free Cash Flow
2,020.54%
169.16%
57.23%
Net Income, GAAP
1,073.71%
30.4%
34.8%
Sales/Revenue/Turnover
- -
34.61%
38.64%
Total Cash Common Dividend
- -
43.78%
31.52%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
50,380
58,742
59,413
74,404
242,939
2025
77,113
83,284
82,997
93,425
336,820
2026
87,175
105,515
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
408
415
258
441.64
1,522
2025
455
404
504.69
653.22
2,017
2026
515.48
435
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
199.04
2025
- -
- -
- -
- -
257.35
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Joon-Oh Yoon
Full Time Employees
528
Sector
Health technology
Industry
Medical specialties
Address
208, Teheran-ro Seoul SL South Korea 06220
IPO Date
Apr 3, 2015
Website
classys.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
CLASSYS Inc. (214150.KQ) develops, manufactures and markets medical aesthetic devices focused on non-invasive skin rejuvenation, lifting, tightening, body contouring and fat reduction treatments worldwide. The company offers ULTRAFORMER MPT for eyebrow lifting; ULTRAFORMER III, an ultrasound device for facial tissue coagulation, eyelid lifting, skin tightening on cheeks, abdomen and thighs; VOLNEWMER (EVERESSE in the US) for skin treatments; SCIZER and CLATUU Alpha for non-invasive subcutaneous fat reduction; Ulfit for improving skin elasticity and subcutaneous tissue in abdomen and thighs; Refit, combining radiofrequency and negative pressure for pain relief, tissue temperature increase and blood flow enhancement; AQUAPURE with four handpieces for acne suction and pain relief; FORSHAPE, an RF system for metabolism boost, circulation and tissue recovery; INTRASURE for lifting, wrinkle reduction, body contouring and cellulite reduction; plus cosmetics under Classys, Cluederm and Skederm brands; and post-2024 merger with Ilooda, expanded HIFU, RF, microneedling RF and laser technologies. Founded in 2007 and headquartered in Seoul, South Korea, at 208 Teheran-ro, Gangnam-gu, CLASSYS operates manufacturing plants in Songpa-gu and Anyang-si, Gyeonggi-do, serving clinics, hospitals and distributors across more than 80 countries in Asia, the Americas, Europe and the Middle East. A subsidiary of BCPE Centur Investments LP (backed by Bain Capital), the company underwent Bain Capital refinancing in April 2024 to support global expansion and new product launches. Recent developments include the 2024 strategic merger with Ilooda enhancing its energy-based device portfolio; a November 2024 US market entry partnership with Cartessa Aesthetics as exclusive distributor for EVERESSE; and a November 2025 acquisition of 77.5% stake in Brazil's JL Health Participacoes SA for 18.27 billion won ($13 million) to bolster South American presence, with a call option for the remaining shares.